Interferons News and Research

RSS

Cannabis compound inhibits SARS-CoV-2 replication in human lung cells

Researchers in the United States have conducted a study showing that a cannabis plant compound inhibited infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human lung cells.

14 Mar 2021

Impact of type I interferon (IFN) autoantibodies in critical COVID-19

A new preprint discusses the pathogenesis of this critical COVID-19 with reference to autoimmune phenomena involving the key antiviral type I interferon pathway.

12 Mar 2021

SARS-CoV-2 is extremely sensitive to type I IFN pre-treatment, study finds

Researchers have found that SARS-CoV-2 is extremely sensitive to type I IFN pre-treatment. Therefore, strategies such as focusing on limiting the production of IFN, rather than its function, could restrict the mechanism of SARS-CoV-2 that increases its viral load with delayed or absent symptoms.

12 Mar 2021

Higher levels of airborne pollen increase SARS-CoV-2 infection rates

When airborne pollen levels are higher, increased SARS-CoV-2 infection rates can be observed. These results were determined by a large-scale study conducted by an international team headed by researchers at the Technical University of Munich and the Helmholtz Zentrum München.

9 Mar 2021

Optimized SARS-CoV-2 vaccine candidate could be less reactogenic, say researchers

A new study, released as a preprint on the bioRxiv* server, reports an optimized coronavirus disease 2019 (COVID-19) vaccine candidate, which, claim the researchers, may be less likely to produce reactions like fevers. It may also have increased protective potential against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen that causes COVID-19.

9 Mar 2021

How do viruses evolve in bats?

Bats have played a crucial epidemiological role in the evolution of many viruses and house many coronaviruses. Until 2002, coronaviruses had been known to cause mild respiratory ailments in human beings. However, this notion changed in the same year when a bat-borne virus caused the severe acute respiratory syndrome (SARS) pandemic.

8 Mar 2021

Apoptosis is an important mediator of pathogenesis in animal coronavirus infection

A new paper in the journal Life presents an early review of the viral factors involved in initiating and effecting apoptosis within infected cells.

8 Mar 2021

SARS-CoV-2 proteins are potent suppressors of innate immunity

A new study describes the strong immune-suppressing activity of SARS-CoV-2 genes, among other coronavirus genes.

5 Mar 2021

Novel host-viral-microbiome interactions during COVID-19 may determine outcome

A new preprint on the medRxiv* server discusses how the underlying disease mechanisms are regulated such that the local or mucosal immune response is distinct from the systemic response.

4 Mar 2021

Coronavirus deranges the immune system in complex and deadly ways

There's a reason soldiers go through basic training before heading into combat: Without careful instruction, green recruits armed with powerful weapons could be as dangerous to one another as to the enemy.

4 Mar 2021

SARS-CoV-2 does not infect the entire body in the same way, finds study

COVID-19, the disease caused by the pandemic coronavirus SARS-CoV-2, is primarily regarded as a respiratory infection. Yet the virus has also become known for affecting other parts of the body in ways not as well understood, sometimes with longer-term consequences, such as heart arrhythmia, fatigue and "brain fog."

24 Feb 2021

Neanderthal gene can confer protection against severe COVID-19, finds study

A new study has detailed how some of the genes in the human genome inherited from Neanderthals appear to confer a protective effect against severe COVID-19.

22 Feb 2021

Some nutritional supplements may help prevent or mitigate COVID-19 severity

A new study in the Journal of dietary supplements shows that nutritional supplements, including several vitamins and the mineral zinc, may be useful in preventing the infection or reducing its severity if caught.

22 Feb 2021

Mucosal delivery of IFNs a good strategy for COVID-19 prophylaxis post-exposure

Researchers from the UK and Germany recently reported a comprehensive characterization of the SARS-CoV-2 response of human nasal epithelial cells, revealing a response dominated by IFN-I/IIIs. Also, recombinant IFN-I/III treatment was found to efficiently block the replication of SARS-CoV-2, which suggests that mucosal delivery of IFNs may be a good strategy for prophylaxis post-exposure.

22 Feb 2021

Humidity created inside facemasks may help combat COVID-19, study finds

A new study, published in the journal Biophysical Journal by researchers at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH), showed that face masks increase the humidity in the air that the mask-wearers inhale. The level of moisture in inhaled air could be linked to lower levels of COVID-19 severity.

16 Feb 2021

Immunosuppressive therapies may be linked to severe COVID-19 in those with multiple sclerosis

A new study examines the associations between immunosuppressive disease-modifying therapies (DMTs) used in MS with adverse outcomes in an international cohort of patients with MS COVID-19.

15 Feb 2021

Humidity created inside the face masks may help combat COVID-19

Masks help protect the people wearing them from getting or spreading SARS-CoV-2, the virus that causes COVID-19, but now researchers from the National Institutes of Health have added evidence for yet another potential benefit for wearers: The humidity created inside the mask may help combat respiratory diseases such as COVID-19.

14 Feb 2021

New mouse model of SARS-CoV-2 infection reflects features of human infection

Now, a new preprint research paper posted to the bioRxiv server reports the development of a modified mouse model that allows productive SARS-CoV-2 infection of the mouse lungs, as well as the exploration of type I and III interferon responses in this condition.

14 Feb 2021

Experimental antiviral drug can significantly speed up recovery for COVID-19 outpatients

A clinical study led by Dr. Jordan Feld, a liver specialist at Toronto Centre for Liver Disease, University Health Network (UHN), showed an experimental antiviral drug can significantly speed up recovery for COVID-19 outpatients – patients who do not need to be hospitalized.

8 Feb 2021

SARS-CoV-2 delays interferon signaling in host cells

A team of scientists from Sweden and India has recently conducted a study to evaluate type I interferon (IFN-I) responses in cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The findings reveal that SARS-CoV-2 infection is associated with a delayed and dysregulated IFN-I response and that pretreatment with IFN-I can reduce the risk of SARS-CoV-2 infection.

7 Feb 2021